A Phase 2 interventional study of Hydroxycarbamid in Sickle Cell Disease, sponsored by Theravia. Recruiting at 7 sites in 2 countries. Open to participants aged 9 Months to 11 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Theravia (part of Norgine) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing hydroxyurea in Anemia, Sickle Cell — 8 open to participants now, 14 under way, 1 of them phase 3. Hydroxyurea · Anemia, Sickle Cell.
Among the 59 studies testing hydroxyurea in Anemia, Sickle Cell, this one is the 29th largest by planned enrollment of the 57 interventional ones that give a count, is the only one that started in 2025, is one of 20 in phase 2, reaches primary completion later than 9 of the 13 other live ones, and was the 57th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →8 of the 59 studies testing hydroxyurea in Anemia, Sickle Cell are open now, in 6 countries. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
Children's Hospital Medical Center, Cincinnati · Sites in Uganda
Ages 11–18
Vanderbilt University Medical Center · Sites in Nigeria
Ages 5–12
Brown University · Sites in Angola
Ages 6 mo–12 yrs
Barau Dikko Teaching Hospital · Sites in Nigeria
Ages 2–16
By country, each count listing its studies:
Hydroxyurea: first FDA approval 1967 (DROXIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 9 Months to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 29 · Phase 3 12 · Phase 4 5
First in 1984; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 50 across the 57 interventional studies. Of the 43 that completed or were terminated, 18 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 59 have an industry lead sponsor. The 10 most frequent:
This study is registered under Theravia, one of the names counted as Norgine. Under that name alone:
Theravia is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Norgine has 7 studies filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
4 of the studies testing hydroxyurea in Anemia, Sickle Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT02286154Children's Hospital Medical Center, CincinnatiTherapeutic Response Evaluation and Adherence Trial (TREAT) | 2026-12 |
| NCT05662098Children's Hospital Medical Center, CincinnatiAlternative Dosing And Prevention of Transfusions (ADAPT) | 2026-12-31 |
| NCT06171217Children's Hospital Medical Center, CincinnatiRealizing Effectiveness Across Continents With Hydroxyurea | 2027-10-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies testing hydroxyurea in Anemia, Sickle Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this interventional, phase II, national, multicentric, non-randomised, open-label study is to evaluate the pharmacokinetics (PK), efficacy and safety of Hydroxycarbamide Paediatric dispersible tablets with a twice daily dosing regimen in children with Sickle Celle Disease between 9 months to 11 years of age.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hydroxycarbamide Pediatric dispersible tablet will be administered twice daily during 12 months.
Drug: Hydroxycarbamid
Hydroxycarbamide Paediatric dispersible tablets will be provided in the form of film-coated dispersible tablets containing 50 mg of hydroxycarbamide. The IMP will be administered as half-strength twice daily, based on the body weight of the patient.
Also known as: Hydroxyurea
Evaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through area under the curve (AUC)
Time frame: 1, 3, 6, 9 and 12 months after treatment initiation
Evaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through time to obtain the maximum concentration (Tmax)
Time frame: 1, 3, 6, 9 and 12 months after treatment initiation
Evaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through maximum plasma concentration (Cmax)
Time frame: 1, 3, 6, 9 and 12 months after treatment initiation
Absolute mean change from baseline in HbF levels
Time frame: Baseline, 3, 6, 9 and 12 months after treatment initiation
HC plasma concentrations and HbF levels
Time frame: Baseline, 3, 6, 9 and 12 months after treatment initiation
Daily AUC (AUC0-24h) at maintenance dose derived from the final PPK model
Time frame: Baseline, 3, 6, 9 and 12 months after treatment initiation
Proportion of patients with a relative difference in Cmax ≥ 30% from BID maintenance dose relative to the one simulated on a once daily regimen giving an equivalent AUC0-24h.
Time frame: Baseline, 3, 6, 9 and 12 months after treatment initiation
Absolute mean change from baseline in haematological parameters
Time frame: Baseline,1, 3, 6, 9 and 12 months after treatment initiation
Acceptability score based on a hedonic face scale evaluated by the child from 3 years old
Time frame: 3 months after treatment initiation
Acceptability score based on a 5-point Likert scale evaluated by the parent(s) or legally acceptable representative(s)
Time frame: 3 months after treatment initiation
Distribution of the scores related to the ease of using the administration kit for treatment administration to the child based on a 5-point Likert scale evaluated by the parent(s) or legally acceptable representative(s)
Score 1 : very difficult to score 5 : very easy
Time frame: 3 months after treatment initiation
Compliance with Hydroxycarbamide Paediatric dispersible tablets administered BID by treatment unit accountability calculated by the pharmacy (patient will bring the kits with used and unused bottles to the pharmacy at each visit)
Time frame: Baseline, 1, 3, 6, 9, 12 months after treatment initiation
Number of SCD events occurring during the study
Time frame: Baseline, 1, 3, 6, 9, 12 months after treatment initiation
Number of adverse events (AEs) and percentage of patients reporting at least one AE
Time frame: Baseline, 1, 3, 6, 9, 12 months after treatment initiation
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Feb 2028, 37 months after the start.
Of 34 industry-sponsored phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's planned 37 months is above that.
Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Feb 2027 → Feb 2028 and completion Feb 2027 → Feb 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hydroxyurea